ADVFN US – Market Content Editor
-
Crypto Reporting Enters the Global Stage: What DAC8 and CARF Will Mean by 2026–2027 – Chainwire
Dubai, United Arab Emirates, August 5th, 2025, Chainwire With international regulatory changes approaching full implementation, Eastern Region Group is advising digital asset stakeholders to begin preparations for compliance with the EU’s DAC8 Directive and the OECD’s Crypto-Asset Reporting Framework (CARF). These frameworks are set to bring crypto-assets under formal tax reporting requirements in over 67…
-
S&P 500 Extends Losing Streak To Five Days As Powell Speech Looms
Stocks fluctuated early in the session on Thursday before mostly lower over the course of the trading day. The major averages all moved to the downside on the day, with the S&P 500 closing lower for the fifth consecutive session. The major averages finished the day off their worst levels but still in negative territory.…
-
NHTSA opens inquiry into Tesla over late crash notifications
The National Highway Traffic Safety Administration (NHTSA) revealed on Thursday that it has initiated an investigation into Tesla (NASDAQ:TSLA) over potential delays in reporting crashes involving the company’s semi-autonomous or self-driving vehicles. According to the agency, several incident reports submitted by Tesla were filed months after the crashes took place, raising concerns that the automaker…
-
Tecnoglass shares drop 8.5% after short report alleges cartel connections
Tecnoglass (NYSE:TGLS) fell 8.5% Thursday following a report from Culper Research claiming that the company’s CEO and COO have links to Colombia’s Sinaloa cartel. The report asserts that leaked Mexican intelligence documents identify Jose and Christian Daes as involved in financial schemes tied to the cartel. Culper Research also alleges that the cartel used Banco…
-
Rent the Runway shares jump 20% following growth-focused recapitalization
Rent the Runway (NASDAQ:RENT) surged 20% after unveiling a major growth recapitalization aimed at reducing debt and fueling expansion. Under the plan, Aranda Principal Strategies (APS) will convert approximately $243 million of debt into common equity at $9.23 per share, marking an 80.9% premium to the recent 30-day average price of $5.10. The recapitalization also…
-
Dynavax shares jump 8% after promising shingles vaccine trial results
Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from its Phase 1/2 trial of Z-1018, the company’s experimental shingles vaccine. The trial showed that Z-1018 produced immune responses comparable to GlaxoSmithKline (NYSE:GSK)’s Shingrix, the leading shingles vaccine, while offering a notably improved tolerability profile. At the selected dose, Z-1018…
-
OSI Systems shares rise 3% on strong FY26 guidance despite Q4 earnings miss
OSI Systems, Inc. (NASDAQ:OSIS) saw its stock climb 2.96% in pre-market trading Thursday after reporting fourth-quarter results and issuing a bullish fiscal 2026 outlook. For the quarter, the security and healthcare technology company posted adjusted earnings of $3.24 per share, up 14% year-over-year, slightly below analysts’ estimate of $3.19. Revenue reached a record $504.99 million,…
-
ScanSource shares climb 3% after strong Q4 results and upbeat FY26 guidance
ScanSource, Inc. (NASDAQ:SCSC) saw its stock rise 3.36% in pre-market trading Thursday after reporting fourth-quarter results that exceeded analyst expectations and providing a positive outlook for fiscal 2026. For the quarter ended June 30, 2025, the Greenville, South Carolina-based technology distributor posted adjusted earnings of $1.02 per share, above the consensus of $0.93. Revenue reached…
-
Gilead shares drop after CVS delays coverage for HIV prevention shot
Gilead Sciences (NASDAQ:GILD) saw its stock decline 2.7% in pre-market trading Thursday following news that CVS Health (NYSE:CVS) will not immediately add the company’s new HIV prevention drug, Yeztugo, to its commercial plans. CVS, the largest U.S. pharmacy benefit manager, cited clinical, financial, and regulatory considerations for the decision. The drug will also not be…
-
Sarepta Therapeutics shares dip after convertible note refinancing
Sarepta Therapeutics (NASDAQ:SRPT) saw its stock fall 3.3% in pre-market trading Thursday following the announcement of a refinancing of roughly $700 million of its 1.25% Convertible Senior Notes due 2027. The precision genetic medicine company reached exchange agreements with select holders of the existing notes. Under these agreements, Sarepta will swap the notes for approximately…